Increased left and right atrial volume indices are associated with decreased survival times post-cardiac arrest.

Cardiac arrest Left atrial volume index Outcomes Pulseless ventricular tachycardia Right atrial volume index Survival time Ventricular fibrillation

Journal

Resuscitation
ISSN: 1873-1570
Titre abrégé: Resuscitation
Pays: Ireland
ID NLM: 0332173

Informations de publication

Date de publication:
01 2022
Historique:
received: 07 06 2021
revised: 14 09 2021
accepted: 13 10 2021
pubmed: 26 10 2021
medline: 25 3 2022
entrez: 25 10 2021
Statut: ppublish

Résumé

Left and right atrial volume indices (LAVI and RAVI) are markers of cardiac remodeling. LAVI and RAVI are associated with worse outcomes in other cardiac conditions. This study aimed to determine the associations of these atrial volume indices with survival time post-cardiac arrest. This was a single center, retrospective study of patients with a sudden cardiac arrest event during index hospitalization from 2014-2018 based on pre-arrest parameters. The analysis was stratified based on whether a pulseless ventricular tachycardia/ventricular fibrillation (pVT/VF) event or a pulseless electrical activity (PEA)/asystole event occurred. Cox proportional hazards regression and model selection with best subsets approach evaluated the association of atrial volume parameters with survival times in the context of other covariates. Of 305 patients studied (64 ± 14 years, 37% female), the mean LAVI was 34.0 ± 15.8 mL/m Among patients with cardiac arrest from ventricular arrhythmias, those with no more than mild left atrial enlargement pre-arrest by LAVI measurement had the best prognosis. Additional studies are indicated to validate the importance of this finding for clinical management decisions. In patients with sudden cardiac arrest associated with ventricular arrhythmias, a left atrial volume index (LAVI) < 34 mL/m

Sections du résumé

BACKGROUND
Left and right atrial volume indices (LAVI and RAVI) are markers of cardiac remodeling. LAVI and RAVI are associated with worse outcomes in other cardiac conditions. This study aimed to determine the associations of these atrial volume indices with survival time post-cardiac arrest.
METHODS
This was a single center, retrospective study of patients with a sudden cardiac arrest event during index hospitalization from 2014-2018 based on pre-arrest parameters. The analysis was stratified based on whether a pulseless ventricular tachycardia/ventricular fibrillation (pVT/VF) event or a pulseless electrical activity (PEA)/asystole event occurred. Cox proportional hazards regression and model selection with best subsets approach evaluated the association of atrial volume parameters with survival times in the context of other covariates.
RESULTS
Of 305 patients studied (64 ± 14 years, 37% female), the mean LAVI was 34.0 ± 15.8 mL/m
CONCLUSION
Among patients with cardiac arrest from ventricular arrhythmias, those with no more than mild left atrial enlargement pre-arrest by LAVI measurement had the best prognosis. Additional studies are indicated to validate the importance of this finding for clinical management decisions.
CONDENSED ABSTRACT
In patients with sudden cardiac arrest associated with ventricular arrhythmias, a left atrial volume index (LAVI) < 34 mL/m

Identifiants

pubmed: 34695443
pii: S0300-9572(21)00429-9
doi: 10.1016/j.resuscitation.2021.10.023
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

306-313

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Sami H Ibrahim (SH)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: shi5vs@virginia.edu.

Kenneth C Bilchick (KC)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: kcb7@virginia.edu.

Matthew S Miller (MS)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: msm3rb@viriginia.edu.

Olivia J Blazek (OJ)

Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: ojb8k@virginia.edu.

Jarred E Strickling (JE)

Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: js9yp@virginia.edu.

Comfort Elumogo (C)

Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: coe9r@virginia.edu.

Robert C Wharton (RC)

Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: rcw4bc@hscmail.mcc.virginia.edu.

Paras Patel (P)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: PRP3A@hscmail.mcc.virginia.edu.

Olivia Ondigi (O)

Department of Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: OKO7GY@hscmail.mcc.virginia.edu.

William J Brady (WJ)

Department of Emergency Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: WB4Z@hscmail.mcc.virginia.edu.

Younghoon Kwon (Y)

Division of Cardiovascular Medicine, University of Washington, Seattle, WA, United States. Electronic address: yhkwon@cardiology.washington.edu.

Sula Mazimba (S)

Division of Cardiovascular Medicine, University of Virginia Health System, Charlottesville, VA, United States. Electronic address: sm8sd@virginia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH